[1] Lade A, Noon L A, Friedman S L. Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer. Curr Opin Oncol, 2014, 26(1):100-107.
[2] Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol, 2019, 71(4):793-801.
[3] Datz C, Muller E, Aigner E. Iron overload and non-alcoholic fatty liver disease. Minerva Endocrinol, 2017, 42(2):173-183.
[4] 中华医学会内分泌学分会. 非酒精性脂肪性肝病与相关代谢紊乱诊疗共识(第二版). 中华内分泌代谢杂志, 2018, 34(7):549-554.
[5] Sumida Y, Yoneda M, Hyogo H, et al. A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol, 2011, 46(2):257-268.
[6] Kim CW, Chang Y, Sung E, et al. Serum ferritin levels predict incident non-alcoholic fatty liver disease in healthy Korean men. Metabolism, 2012, 61(8):1182-1188.
[7] Carmen GY, Victor SM. Signalling mechanisms regulating lipolysis. Cell Signal, 2006, 18(4):401-408.
[8] Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol, 2013, 10(6):330-344.
[9] Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med, 2012, 52(1):59-69.
[10] Mateo-Gallego R, Calmarza P, Jarauta E, et al. Serum ferritin is a major determinant of lipid phenotype in familial combined hyperlipidemia and familial hypertriglyceridemia. Metabolism, 2010, 59(2):154-158.
[11] Oshaug A, Bugge KH, Bjonnes C H, et al. Associations between serum ferritin and cardiovascular risk factors in healthy young men. a cross sectional study. Eur J Clin Nutr, 1995, 49(6):430-438.
[12] Ellidag HY, Eren E, Akdag M, et al. The relationship between serum ferritin levels and serum lipids and HDL function with respect to age and gender. Ukr Biochem J, 2016, 88(6):76-86.
[13] Corradini E, Meynard D, Wu Q, et al. Serum and liver iron differently regulate the bone morphogenetic protein 6 (BMP6)-SMAD signaling pathway in mice. Hepatology, 2011, 54(1):273-284.
[14] Ryu S, Chang Y, Kim SG, et al. Serum uric acid levels predict incident nonalcoholic fatty liver disease in healthy Korean men. Metabolism, 2011, 60(6):860-866.
[15] Liu Z, Que S, Zhou L, et al. Dose-response relationship of serum uric acid with metabolic syndrome and non-alcoholic fatty liver disease incidence: a meta-analysis of prospective studies. Sci Rep, 2015, 5:14325.
[16] Kodama S, Saito K, Yachi Y, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care, 2009, 32(9):1737-1742. |
